By otakuyassine3@gmail.com 
Arvinas, Inc. (NASDAQ:ARVN – Free Report) – Investment analysts at HC Wainwright issued their Q3 2025 earnings estimates for shares of Arvinas in a research report issued to clients and investors on Wednesday, February 12th. HC Wainwright analyst A. Fein expects that the company will post earnings of ($0.54) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $87.00 target price on the stock. The consensus estimate for Arvinas’ current full-year earnings is ($3.22) per share. HC Wainwright also issued estimates for Arvinas’ FY2025 earnings at ($2.13) EPS, FY2026 earnings at ($3.54) EPS, FY2027 earnings at ($2.54) EPS and FY2028 earnings at $2.77 EPS.
Arvinas (NASDAQ:ARVN – Get Free Report) last announced its quarterly earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($1.07) by $0.44. During the same quarter last year, the firm posted ($2.53) EPS.
A number of other research analysts have also recently commented on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arvinas in a research report on Friday, February 7th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $82.00 target price (down previously from $88.00) on shares of Arvinas in a research report on Wednesday, February 12th. Oppenheimer upped their target price on shares of Arvinas from $40.00 to $45.00 and gave the company an “outperform” rating in a research report on Wednesday, February 12th. Stifel Nicolaus decreased their target price on shares of Arvinas from $63.00 to $51.00 and set a “buy” rating on the stock in a research report on Wednesday, February 12th. Finally, Stephens began coverage on shares of Arvinas in a research report on Monday, November 18th. They issued an “overweight” rating and a $55.00 target price on the stock. Thirteen equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Arvinas presently has a consensus rating of “Buy” and an average target price of $60.00.
Read Our Latest Report on Arvinas
Arvinas Trading Up 3.6 %
Shares of ARVN stock opened at $18.31 on Monday. The company’s 50-day moving average price is $18.75 and its 200-day moving average price is $23.10. Arvinas has a twelve month low of $16.61 and a twelve month high of $53.08. The stock has a market cap of $1.26 billion, a price-to-earnings ratio of -3.92 and a beta of 1.88.
Institutional Trading of Arvinas
Institutional investors and hedge funds have recently bought and sold shares of the business. nVerses Capital LLC purchased a new stake in shares of Arvinas during the third quarter worth approximately $39,000. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Arvinas by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,483 shares of the company’s stock worth $61,000 after buying an additional 440 shares during the period. KBC Group NV increased its stake in shares of Arvinas by 77.0% during the fourth quarter. KBC Group NV now owns 2,885 shares of the company’s stock worth $55,000 after buying an additional 1,255 shares during the period. Quantbot Technologies LP increased its stake in shares of Arvinas by 147.3% during the third quarter. Quantbot Technologies LP now owns 4,367 shares of the company’s stock worth $108,000 after buying an additional 2,601 shares during the period. Finally, Exchange Traded Concepts LLC increased its stake in shares of Arvinas by 37.0% during the third quarter. Exchange Traded Concepts LLC now owns 6,659 shares of the company’s stock worth $164,000 after buying an additional 1,798 shares during the period. 95.19% of the stock is currently owned by hedge funds and other institutional investors.
Arvinas Company Profile
Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.
Further Reading
Receive News & Ratings for Arvinas Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Arvinas and related companies with MarketBeat.com’s FREE daily email newsletter.